雅塑youngsure品牌怎么样 申请店铺

我要投票 雅塑youngsure在减肥药行业中的票数:276 更新时间:2025-04-02
雅塑youngsure是哪个国家的品牌?「雅塑youngsure」是 重庆植恩药业有限公司 旗下著名品牌。该品牌发源于重庆,由创始人黄山在2003期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力雅塑youngsure品牌出海!通过在本页面挂载雅塑youngsure品牌的产品链接和联系邮箱,可以提高雅塑youngsure产品曝光!跨境电商爆单神器,目前只要100元/年哦~

雅塑youngsure怎么样

重庆植恩药业有限公司创办于2001年,是立足于重庆的一家集研发、生产和销售一体化的新兴医药企业,是一家集两江药物研发中心、手性工程中心和新药设计工程中心等三大研发中心、原料药生产基地、制剂生产基地和销售总部的集团公司。

植恩药业高度重视研发和创新,并已具备了很强的研发能力。公司的两江药物研发中心为重庆市唯一的国家级“药物先进制造技术国家地方联合工程研究中心”,手性工程中心和新药设计工程中心均为重庆市级工程中心,公司还设有重庆市级博士后流动站,为公司提供持续的高级人才储备。经过多年的努力,公司已经获得新药证书33项、临床批件32项、生产批件51项;申请国家发明专利数十项,其中已获国外专利授权2件,国内专利授权12件。公司已开展研发项目32项,承担包括国家重大新药创制项目(“11.5”和“12.5”)等70余项各类课题,并获得全国及省级奖项数十项。目前在研项目涉及神经系统药物、代谢系统药物、消化系统药物及其他类药物,其中神经系统药物已成为公司发展的主要方向,其中包括化药1类新药2项、中药5类新药1项。

植恩药业产业化能力较强,产能正逐步扩大。现有原料药生产基地年生产能力超过40吨,新建82000平方原料药生产基地将使产能提高到每年60吨-80吨,核心API品种奥利司他质量及产能达到国际先进水平,产品已热销巴西、澳大利亚、德国、波兰、新加坡和韩国,且已经在美国和印度递交上市申请,未来国际市场将进一步拓宽。现有制剂生产线可生产胶囊剂、颗粒剂、片剂、栓剂等剂型,在建制剂生产线将新增冻干剂型、小/大容量注射液等剂型,在建制剂产业化基地建筑面积33330㎡。

公司产品丰富,后续产品充足。目前主打产品有奥利司他、盐酸多奈哌齐、盐酸罗匹尼罗、甲磺司特等,即将上市的重点产品包括盐酸他利克索和盐酸兰地洛尔等。

植恩药业具有强大的一级市场到达终端市场的分销商网络。目前拥有零售终端及医院终端销售人员500余人。产品覆盖30个城市2000多家医院,40000家药店。外贸方面,原料药出口到全球20多个国家。

公司以“木直因心,植药为仁”为座右铭,以“创建中国医药与健康服务的领先企业”为发展目标。在强大的医药研发团队、高效的医学注册能力、广泛坚固的医药渠道网络、专业化的市场销售能力、权威的政府事务及专业机构合作能力支持下,立志将公司打造成行业内知名的高新技术医药企业。

Founded in 2001, Chongqing Zhien Pharmaceutical Co., Ltd. is a new pharmaceutical enterprise integrating R & D, production and sales based in Chongqing. It is a group company integrating three R & D centers, API production base, preparation production base and sales headquarters, including Liangjiang pharmaceutical R & D center, chiral Engineering Center and new drug Design Engineering Center. Zhien pharmaceutical attaches great importance to R & D and innovation, and has a strong R & D capability. Liangjiang pharmaceutical R & D center of the company is the only national level "national and local joint engineering research center of advanced pharmaceutical manufacturing technology" in Chongqing. The chirality Engineering Center and new drug design engineering center are both Chongqing Municipal Engineering Center. The company also has Chongqing Municipal Post Doctoral mobile station to provide the company with continuous senior talent reserve. After years of efforts, the company has obtained 33 new drug certificates, 32 clinical approvals and 51 production approvals; applied for dozens of national invention patents, including 2 foreign patent authorizations and 12 domestic patent authorizations. The company has carried out 32 R & D projects, undertaken more than 70 various subjects including national major new drug development projects ("11.5" and "12.5"), and won dozens of national and provincial awards. At present, the research projects involve nervous system drugs, metabolic system drugs, digestive system drugs and other drugs, among which nervous system drugs have become the main development direction of the company, including 2 chemical drugs of class 1 and 1 Traditional Chinese medicine of class 5. The industrialization capacity of Zhien pharmaceutical industry is strong, and the production capacity is gradually expanding. The annual production capacity of the existing API production base is more than 40 tons. The newly built 82000 square meters API production base will increase the production capacity to 60-80 tons per year. The quality and production capacity of the core API variety ollistat reach the international advanced level. The products have been sold well in Brazil, Australia, Germany, Poland, Singapore and South Korea, and have submitted listing applications in the United States and India. In the future, the international market It will be further expanded. The existing preparation production line can produce capsule, granule, tablet, suppository and other dosage forms. The new dosage forms, such as freeze-drying dosage form, small / large volume injection, will be added to the preparation production line under construction. The construction area of the preparation industrialization base under construction is 33330 ㎡. The company has abundant products and sufficient follow-up products. At present, the main products are orlistat, donepezil hydrochloride, ropinirol hydrochloride, mesylate, etc. the key products to be launched include talicosol hydrochloride and randilol hydrochloride, etc. Zhien pharmaceutical has a strong distributor network from primary market to terminal market. At present, it has more than 500 retail terminal and hospital terminal sales personnel. The products cover more than 2000 hospitals and 40000 pharmacies in 30 cities. In terms of foreign trade, APIs are exported to more than 20 countries around the world. The company takes the motto of "wood for heart, planting medicine for humanity" and the development goal of "building a leading enterprise of Chinese medicine and health service". With the support of a strong pharmaceutical R & D team, efficient medical registration ability, extensive and solid pharmaceutical channel network, professional marketing ability, authoritative government affairs and cooperation ability of professional institutions, we are determined to build the company into a well-known high-tech pharmaceutical enterprise in the industry.

本文链接: https://brand.waitui.com/918e6e5a8.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

加力扩围发力显效,“两新”政策激发消费活力

4月1日,国家发展改革委消息显示,今年前两个月,“两新”政策进一步发力显效,带动设备工器具购置投资同比增长18%,社会消费品零售总额同比增长4%,继续发挥扩消费、稳投资、促转型、惠民生的重要作用。国家发展改革委指出,“两新”政策有效激发了消费活力。今年超长期特别国债支持消费品以旧换新资金规模增加至3000亿元,相较去年的资金规模翻了一番。首批810亿元资金于1月6日第一时间下达,延续2024年工作基础,扩围支持手机、平板、智能手表手环等数码产品购新。(证券时报)

2小时前

2024年中国为欧盟汽车进口最大来源国

4月1日,欧盟发布2024年欧盟汽车行业贸易数据,中国以127亿欧元进口额成为欧盟汽车进口最大来源国,欧方称,2019-2024五年间,欧盟自中国进口汽车增幅高达1591.3%;尽管如此,2024年欧盟对华汽车贸易保持顺差,对华出口高达145亿欧元。2024年,欧盟共出口汽车540万辆,进口汽车400万辆。与2019年相比,出口数量下降了13.2%,进口数量则减少了3.0%。(界面)

2小时前

业绩承诺仅完成6.7%,三鑫医疗高溢价投资面临追偿难

三年累计不低于4200万元的业绩承诺,实际完成280.42万元,完成率仅为6.7%,业绩承诺方暂时无法拿出充足的资金进行股份回购补偿。近日,三鑫医疗一则关于参股公司业绩承诺实现情况专项说明的公告引发众多投资者关注。有受访投行人士分析,高业绩承诺对应的一定是高估值,高估值就意味着高风险,这也提醒上市公司在投资时要紧紧围绕自身战略进行布局,真正做好风险控制。(上证报)

2小时前

全球风险资产震荡,市场静待关税靴子落地

美国即将于4月2日启动对等关税,引发市场连锁反应。美股三大指数上周集体下挫,亚太市场同步承压,避险资金则推动黄金现货价格触及3149.03美元/盎司的历史高位。随着政策实施时点临近,市场对美国经济政策框架的能见度逐步提升。部分机构表示,政策的可预测性上升,积极信号正在酝酿;也有机构对风险资产的表现感到担忧。尽管短期波动性骤增,但市场普遍认为,4月2日将为接下来几个月的金融市场走向定下基调。(中证网)

2小时前

中信建投:电解铝强调清洁能源代替,绿证市场有望加速成长

36氪获悉,中信建投证券研报显示,近期,工业和信息化部等十部门发布关于印发《铝产业高质量发展实施方案(2025—2027年)》。具体来看,《方案》鼓励企业参与光伏、风电等可再生能源和氢能、储能系统开发建设。推进氢氧化铝焙烧、铝用阳极焙烧环节实施清洁能源替代。在我国能耗双控转型的背景下,高耗能企业的清洁用能替代需求有望持续增长,有助于绿电、绿证市场的加速发展,有利于风光项目环境价值的兑现。

2小时前

本页详细列出关于泰尔维亭的品牌信息,含品牌所属公司介绍,泰尔维亭所处行业的品牌地位及优势。
咨询